Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kyle Bass
Pharma
Supreme Court upholds pharma's most-hated patent challenge
Dealing a blow to branded drugmakers, the U.S. Supreme Court found that inter partes review patent challenges are constitutional.
Eric Sagonowsky
Apr 24, 2018 4:35pm
SCOTUS hears inter partes review arguments
Nov 27, 2017 2:40pm
Biogen wins appeal in Tecfidera patient-death suit
May 16, 2017 12:08pm
Bass blames 'pharma cabal' for patent-challenge setbacks
Apr 12, 2017 11:55am
Court nixes Ampyra patents, teeing up 2018 generics
Apr 3, 2017 10:33am
Biogen sticks it to Kyle Bass with Tecfidera IPR win
Mar 22, 2017 11:45am
